CA1316133C - Method of using bar1 for secreting foreign proteins - Google Patents
Method of using bar1 for secreting foreign proteinsInfo
- Publication number
- CA1316133C CA1316133C CA000521206A CA521206A CA1316133C CA 1316133 C CA1316133 C CA 1316133C CA 000521206 A CA000521206 A CA 000521206A CA 521206 A CA521206 A CA 521206A CA 1316133 C CA1316133 C CA 1316133C
- Authority
- CA
- Canada
- Prior art keywords
- promoter
- fragment
- gene
- cell
- barl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 127
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 35
- 101150071434 BAR1 gene Proteins 0.000 title claims abstract description 13
- 230000003248 secreting effect Effects 0.000 title claims abstract description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 34
- 108020004414 DNA Proteins 0.000 claims abstract description 30
- 108091026890 Coding region Proteins 0.000 claims abstract description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 28
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 26
- 108010076181 Proinsulin Proteins 0.000 claims abstract description 22
- 101150045458 KEX2 gene Proteins 0.000 claims abstract description 15
- 238000012545 processing Methods 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 230000037361 pathway Effects 0.000 claims abstract description 12
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims abstract description 7
- 230000001131 transforming effect Effects 0.000 claims abstract description 5
- 230000004927 fusion Effects 0.000 claims description 41
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 238000003776 cleavage reaction Methods 0.000 claims description 17
- 230000007017 scission Effects 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 241000233866 Fungi Species 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 108010087967 type I signal peptidase Proteins 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 5
- 241000221960 Neurospora Species 0.000 claims description 4
- 101100378536 Ovis aries ADRB1 gene Proteins 0.000 claims description 4
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 230000014621 translational initiation Effects 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims 2
- 101900206827 Schizosaccharomyces pombe Alcohol dehydrogenase Proteins 0.000 claims 2
- 230000034659 glycolysis Effects 0.000 claims 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 101900084120 Saccharomyces cerevisiae Triosephosphate isomerase Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 10
- 239000013612 plasmid Substances 0.000 description 154
- 239000012634 fragment Substances 0.000 description 147
- 210000004027 cell Anatomy 0.000 description 43
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 34
- 230000004888 barrier function Effects 0.000 description 32
- 239000000047 product Substances 0.000 description 17
- 102000004594 DNA Polymerase I Human genes 0.000 description 16
- 108010017826 DNA Polymerase I Proteins 0.000 description 16
- 238000010276 construction Methods 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 230000029087 digestion Effects 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 238000003556 assay Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000013519 translation Methods 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 108010068380 arginylarginine Proteins 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 125000001475 halogen functional group Chemical group 0.000 description 6
- 230000007030 peptide scission Effects 0.000 description 6
- 241001646716 Escherichia coli K-12 Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000013011 mating Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 3
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 3
- 241001672648 Vieira Species 0.000 description 3
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- 239000003016 pheromone Substances 0.000 description 3
- 108010066381 preproinsulin Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101100352919 Caenorhabditis elegans ppm-2 gene Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- 101100223032 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) dapB gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101150028158 STE13 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- -1 i.e. Polymers 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101710096444 Killer toxin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100171805 Mus musculus Efna3 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- IFLVGRRVGPXYON-UHFFFAOYSA-N adci Chemical compound C12=CC=CC=C2C2(C(=O)N)C3=CC=CC=C3CC1N2 IFLVGRRVGPXYON-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79130585A | 1985-10-25 | 1985-10-25 | |
| US791,305 | 1985-10-25 | ||
| USPCT/US86/02198 | 1986-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1316133C true CA1316133C (en) | 1993-04-13 |
Family
ID=25153298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000521206A Expired - Fee Related CA1316133C (en) | 1985-10-25 | 1986-10-23 | Method of using bar1 for secreting foreign proteins |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0243465A1 (cs) |
| JP (1) | JP2523562B2 (cs) |
| CN (1) | CN1027179C (cs) |
| AU (2) | AU6543286A (cs) |
| CA (1) | CA1316133C (cs) |
| CZ (1) | CZ284251B6 (cs) |
| DK (1) | DK320287D0 (cs) |
| FI (1) | FI872801A0 (cs) |
| HU (1) | HU206897B (cs) |
| IE (1) | IE63822B1 (cs) |
| SK (1) | SK776486A3 (cs) |
| UA (1) | UA41863C2 (cs) |
| WO (1) | WO1987002670A1 (cs) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK58285D0 (da) * | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| EP0310137B1 (en) * | 1987-10-02 | 1994-01-26 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5206699A (en) * | 1988-05-06 | 1993-04-27 | Gersan Establishment | Sensing a narrow frequency band of radiation and gemstones |
| AU633020B2 (en) * | 1988-07-23 | 1993-01-21 | Novozymes Delta Limited | New secretory leader sequences |
| AU7493491A (en) * | 1990-03-13 | 1991-10-10 | Hawaii Biotechnology Group, Inc. | (neurospora) expression system |
| DK82893D0 (da) * | 1993-07-08 | 1993-07-08 | Novo Nordisk As | Peptid |
| BRPI9607646B1 (pt) | 1995-03-17 | 2016-07-05 | Novo Nordisk As | vetor de expressão recombinante, célula fúngica, método para produzir uma enzima apresentando atividade de endoglucanase e para prover clarificação da cor nas roupas de lavagem, composição de lavanderia , uso da enzima, e, composição de enzima |
| DK1975177T3 (da) | 1996-03-01 | 2011-07-25 | Novo Nordisk As | Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf |
| DE60139110D1 (de) | 2000-01-10 | 2009-08-13 | Maxygen Holdings Ltd | G-csf konjugate |
| DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| CA2469846A1 (en) | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
| AU2002249096B2 (en) | 2001-03-22 | 2007-06-28 | Novo Nordisk Health Care Ag | Coagulation factor VII derivatives |
| US6534059B2 (en) | 2001-06-05 | 2003-03-18 | Advanced Biotherapy, Inc. | Compositions and methods for treating hyperimmune response in the eye |
| MXPA04002833A (es) | 2001-09-27 | 2004-07-15 | Novo Nordisk Healthcare Ag | Polipeptidos de factor vii de coagulacion humano. |
| CN101870729A (zh) | 2003-09-09 | 2010-10-27 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| EP2360181B1 (en) | 2005-04-18 | 2013-09-18 | Novo Nordisk A/S | IL-21 variants |
| US9056921B2 (en) | 2005-08-16 | 2015-06-16 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
| EP2316930A1 (en) | 2005-09-14 | 2011-05-04 | Novo Nordisk Health Care AG | Human coagulation factor VII polypeptides |
| US20100159512A1 (en) | 2006-03-06 | 2010-06-24 | Kurt Osther | Method for the preparation of recombinant human thrombin and fibrinogen |
| CA2663083A1 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| WO2008037735A1 (en) | 2006-09-27 | 2008-04-03 | Novo Nordisk A/S | Method for making maturated insulin polypeptides |
| EP2076533B1 (en) | 2007-05-02 | 2014-10-08 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| MX338336B (es) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| PL3225248T3 (pl) | 2008-07-23 | 2023-11-27 | Ambrx, Inc. | Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania |
| US8349325B2 (en) | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
| EP2406282A1 (en) | 2009-03-11 | 2012-01-18 | Novo Nordisk A/S | Interleukin-21 variants having antagonistic binding to the il-21 receptor |
| US20120282285A1 (en) | 2009-07-17 | 2012-11-08 | Rigshospitalet | Masp isoforms as inhibitors of complement activation |
| CN102666570B (zh) | 2009-12-01 | 2015-12-02 | 诺沃—诺迪斯克有限公司 | 新的肽基α-羟基甘氨酸α-酰胺化裂合酶 |
| EP2516454A4 (en) | 2009-12-21 | 2013-05-22 | Ambrx Inc | MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND ITS USES |
| BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
| US9815876B2 (en) | 2010-03-05 | 2017-11-14 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| US20110229921A1 (en) | 2010-03-18 | 2011-09-22 | Abbott Laboratories | METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS |
| WO2011163558A1 (en) | 2010-06-25 | 2011-12-29 | Abbott Laboratories | Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies |
| NZ607069A (en) | 2010-08-17 | 2014-10-31 | Ambrx Inc | Modified relaxin polypeptides and their uses |
| AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
| US20120115244A1 (en) | 2010-11-09 | 2012-05-10 | Abbott Laboratories | Materials and methods for immunoassay of pterins |
| CN107090441A (zh) | 2010-12-09 | 2017-08-25 | 巴斯德研究所 | 用于获得高产量重组蛋白表达的基于mgmt的方法 |
| DK2788478T3 (en) | 2011-12-09 | 2017-10-09 | Pasteur Institut | Multiplex IMMUNSCREENINGSASSAY |
| US8993248B2 (en) | 2011-12-31 | 2015-03-31 | Abbott Laboratories | Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use |
| SG11201403988WA (en) | 2012-02-09 | 2014-10-30 | Var2 Pharmaceuticals Aps | Targeting of chondroitin sulfate glycans |
| EP2906693A1 (en) | 2012-10-15 | 2015-08-19 | Novo Nordisk Health Care AG | Coagulation factor vii polypeptides |
| JP2014128262A (ja) * | 2012-11-27 | 2014-07-10 | Kirin Brewery Co Ltd | 接合能を持つ酵母細胞株のスクリーニング方法 |
| BR112020022288A2 (pt) | 2018-05-01 | 2021-02-23 | Ambrx, Inc. | método para otimizar a expressão de anticorpos |
| US20210278406A1 (en) | 2018-07-13 | 2021-09-09 | Varct Diagnostic Aps | Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa |
| US12049485B2 (en) | 2018-09-11 | 2024-07-30 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| AU2020223031B2 (en) | 2019-02-12 | 2024-08-29 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-TLR agonist conjugates |
| CN115243726B (zh) | 2020-03-11 | 2025-07-15 | 北京泰德制药股份有限公司 | 白介素-2多肽偶联物及其使用方法 |
| WO2021211331A1 (en) | 2020-04-13 | 2021-10-21 | Abbott Point Of Care Inc. | METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE |
| US20220043000A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Methods and kits for detecting sars-cov-2 protein in a sample |
| US20230302150A1 (en) | 2020-08-20 | 2023-09-28 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| EP4271998A1 (en) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
| JP2024512775A (ja) | 2021-04-03 | 2024-03-19 | アンブルックス，インコーポレイテッド | 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用 |
| CN115806889B (zh) * | 2022-09-28 | 2024-06-11 | 山东大学 | 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4546082A (en) * | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4613572A (en) * | 1983-08-15 | 1986-09-23 | Kansas State University Research Foundation | Yeast BAR1 gene plasmid |
| JPS61247384A (ja) * | 1984-10-18 | 1986-11-04 | チモ−ジエネテイツクス インコ−ポレ−テツド | 酵母中でプラスミノ−ゲン活性化因子を発現する方法 |
| DE3537176C2 (de) * | 1984-10-18 | 1994-06-09 | Zymogenetics Inc | Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung |
-
1986
- 1986-10-20 JP JP61505713A patent/JP2523562B2/ja not_active Expired - Fee Related
- 1986-10-20 WO PCT/US1986/002198 patent/WO1987002670A1/en active Application Filing
- 1986-10-20 HU HU865248A patent/HU206897B/hu not_active IP Right Cessation
- 1986-10-20 AU AU65432/86A patent/AU6543286A/en not_active Abandoned
- 1986-10-20 UA UA4203156A patent/UA41863C2/uk unknown
- 1986-10-20 EP EP86906638A patent/EP0243465A1/en not_active Withdrawn
- 1986-10-23 CA CA000521206A patent/CA1316133C/en not_active Expired - Fee Related
- 1986-10-23 IE IE280486A patent/IE63822B1/en not_active IP Right Cessation
- 1986-10-25 CN CN86107554A patent/CN1027179C/zh not_active Expired - Lifetime
- 1986-10-27 CZ CS867764A patent/CZ284251B6/cs not_active IP Right Cessation
- 1986-10-27 SK SK7764-86A patent/SK776486A3/sk unknown
-
1987
- 1987-06-23 DK DK320287A patent/DK320287D0/da not_active Application Discontinuation
- 1987-06-24 FI FI872801A patent/FI872801A0/fi not_active Application Discontinuation
-
1991
- 1991-04-02 AU AU74003/91A patent/AU676132B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HU206897B (en) | 1993-01-28 |
| JPS63501614A (ja) | 1988-06-23 |
| DK320287A (da) | 1987-06-23 |
| SK279041B6 (sk) | 1998-06-03 |
| FI872801A7 (fi) | 1987-06-24 |
| IE862804L (en) | 1987-04-25 |
| AU7400391A (en) | 1991-07-18 |
| AU6543286A (en) | 1987-05-19 |
| JP2523562B2 (ja) | 1996-08-14 |
| IE63822B1 (en) | 1995-06-14 |
| EP0243465A1 (en) | 1987-11-04 |
| WO1987002670A1 (en) | 1987-05-07 |
| FI872801A0 (fi) | 1987-06-24 |
| CZ776486A3 (en) | 1996-09-11 |
| CZ284251B6 (cs) | 1998-10-14 |
| CN1027179C (zh) | 1994-12-28 |
| CN86107554A (zh) | 1987-08-26 |
| DK320287D0 (da) | 1987-06-23 |
| AU676132B2 (en) | 1997-03-06 |
| HUT43624A (en) | 1987-11-30 |
| SK776486A3 (en) | 1998-06-03 |
| UA41863C2 (uk) | 2001-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1316133C (en) | Method of using bar1 for secreting foreign proteins | |
| CA1340772C (en) | Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences | |
| US5037743A (en) | BAR1 secretion signal | |
| CA1340547C (en) | Novel secretory leader sequences for yeasts | |
| EP0123544A2 (en) | Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor | |
| CA2090969C (en) | Production of insulin-like growth factor-1 in methylotrophic yeast cells | |
| US5102789A (en) | Production of epideramal growth factor in pichia pastoris yeast cells | |
| EP0220689B1 (en) | Method of using bar1 for secreting foreign proteins | |
| CA2085308C (en) | Dibasic endoprotease fused to endoplasmic reticulum retention signal and use thereof | |
| US5612198A (en) | Production of insulin-like growth factor-1 in methylotrophic yeast cells | |
| JP4187796B2 (ja) | 酵母で発現されたｎ末端伸長タンパク質 | |
| US7198919B1 (en) | Use of alpha factor sequences in yeast expression systems | |
| JP3135550B2 (ja) | 成熟異種タンパク質、特にヒルジン、の製造のための改良された酵母株、および対応するヒルジンの製造法 | |
| US5217891A (en) | DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides | |
| CA1314830C (en) | Bar1 secretion signal | |
| US5879926A (en) | Yeast strains for the production of mature heterologous proteins, especially hirudin | |
| EP1097228B1 (en) | Method of making proteins in transformed yeast cells | |
| WO1991002057A1 (en) | Polypeptide production in fungi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |